查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
阿達木單抗全球市場 - 2022-2029
市場調查報告書
商品編碼
1140667

阿達木單抗全球市場 - 2022-2029

Global Adalimumab Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年阿達木單抗市場價值 38.294 億美元。預計在預測期內（2022-2029 年）將以 5.2% 的複合年增長率增長。

阿達木單抗是一種治療類風濕性關節炎 (RA)、幼年特發性關節炎 (JIA)、銀屑病關節炎 (PsA)、強直性脊柱炎 (AS)、克羅恩病 (CD) 和斑塊型銀屑病 (Ps) 的治療藥物。名稱“修美樂”。阿達木單抗是一種重組人 IgG1 單克隆抗體，靶向腫瘤壞死因子 (TNF)，通過與腫瘤壞死因子結合發揮作用。它通過結合腫瘤壞死因子 (TNF) 並抑制其與細胞表面 TNF 受體 p55 和 p75 的相互作用而起作用。裂解表達表面腫瘤壞死因子的細胞。有效調節由 TNF 誘導或調節的生物反應，這些反應涉及與白細胞遷移有關的粘附分子水平的變化。

阿達木單抗是使用噬菌體展示技術開發的具有人源重鍊和輕鏈可變區以及人 IgG1:k 恆定區的抗體。該抗體是通過重組 DNA 技術在哺乳動物細胞表達系統中產生的。該產品以一次性預填充筆或一次性 1 mL 填充玻璃注射器的形式提供。

市場動態

自身免疫性疾病患病率上升推動市場增長

由於自身免疫性疾病的患病率上升，對阿達木單抗的需求增加推動了市場。根據國家幹細胞基金會 (NSCF) 的數據，據說世界上大約 4% 的人口受到一種或另一種自身免疫性疾病的影響。類風濕性關節炎、強直性脊柱炎、克羅恩病、銀屑病關節炎和尋常型銀屑病是最常見的自身免疫性疾病。據美國銀屑病基金會稱，世界上大約 2% 到 3% 的人口，即 1.25 億人患有銀屑病。大約 30% 的銀屑病患者會發展為銀屑病關節炎，這是一種導致關節畸形和殘疾的慢性炎症性關節炎。強直性脊柱炎影響全世界約 0.1% 至 1.4% 的人。男性比女性更常見。根據關節炎基金會的數據，大約 80% 的人會在 30 歲之前出現強直性脊柱炎的症狀。 45 歲及以上的所有患者中約有 5% 會發展為強直性脊柱炎。

完善阿達木單抗報銷制度促進市場增長

擴大阿達木單抗的保險範圍將推動市場增長。阿達木單抗的覆蓋率約為 99%，包括 Medicare Part D 和 Medicaid 患者。中國監管機構還將阿達木單抗列入國家醫保藥品目錄（NRDL）。中國監管機構已將阿達木單抗與製藥公司的價格平均降低了 61%。

與使用阿達木單抗相關的副作用阻礙市場增長

與使用阿達木單抗相關的副作用正在阻礙市場。在患者中可能會觀察到一些副作用，包括噁心、腹痛、高脂血症、血尿、高膽固醇血症、背痛、皮疹、頭痛和高血壓。在阿達木單抗的注射部位觀察到發紅、腫脹和疼痛。它還增加了真菌、細菌和病毒感染在全身發展和傳播的風險。由細菌、分枝桿菌、侵入性真菌、病毒、寄生蟲等引起的機會性感染，如曲霉菌病、芽生菌病、念珠菌病、球孢子菌病、組織胞漿菌病、軍團菌病、李斯特菌病、肺孢子菌病、肺結核病等。接受患者的認可。

COVID-19 影響分析

阿達木單抗的全球市場受到 COVID-19 疫情的極大刺激。多個研究機構、組織和公司專注於評估阿達木單抗治療 COVID-19 的潛力。針對 COVID-19 的阿達木單抗的研發活動也在增加。 COVID-19 患者在使用抗 TNF 藥物治療炎症性腸病和炎症性關節炎時不太可能住院。抗 TNF 療法可有效中和 TNF，TNF 是細胞因子反應的關鍵組成部分，是 COVID-19 有害高炎症階段的一部分。因此，我們專注於進行臨床試驗，以測試阿達木單抗對 COVID-19 患者的療效和安全性。例如，2020 年 10 月，英國牛津大學的研究人員計劃啟動一項新的臨床試驗，評估阿達木單抗在居家社區護理環境中治療 COVID-19 患者的療效。臨床試驗 (AVID-CC) 將由牛津臨床試驗和研究單位 (OCTRU) 領導，並將招募多達 750 名來自社區護理院的患者。

流行病學

2019 年全球疾病負擔、傷害和風險因素研究 (GBD) 估計，2019 年類風濕性關節炎 (RA) 的患病率為 326 萬。女性受到影響的可能性是男性的兩到三倍。大約有 12 名女性和 20 名男性中有 1 名在其一生中會患上炎症性自身免疫性風濕病。根據 Giegerich E 等 2018 年的數據，2017 年克羅恩病的診斷患病率在亞太低收入地區為每 10 萬人 6 人，在高收入亞太地區為每 10 萬人 46 人，在歐洲為每 10 萬人 46 人。說，北美每10萬人中有133例，每10萬人中有210例。克羅恩病的確診患病率在 40-54 歲的人群中最高。強直性脊柱炎患病率歐洲為23.8/萬，亞洲為16.7/萬，北美為31.9/萬，拉丁美洲為10.2/萬，非洲為1萬，人均確診7.4。

市場細分

預計阿達木單抗市場將佔類風濕關節炎的最大份額

按疾病類型分為類風濕關節炎、銀屑病關節炎、克羅恩病、潰瘍性結腸炎等。預計類風濕關節炎部分將佔據阿達木單抗治療市場的最大份額。類風濕性關節炎是最常見的自身免疫性關節炎，影響關節、結締組織、肌肉、肌腱和纖維組織。類風濕性關節炎的特徵是關節疼痛、僵硬、腫脹和關節運動減少。它會導致手腕和手腳小關節疼痛和腫脹。類風濕性關節炎會干擾患者的活動能力並導致永久性關節損傷。類風濕性關節炎的患病率在世界範圍內呈上升趨勢。根據世界衛生組織 (WHO) 的數據，類風濕性關節炎的患病率在全球範圍內為 0.3% 至 1%。女性也比男性更常見。

從分銷渠道來看，預計醫院藥房在預測期內將實現高增長

市場按分銷渠道分為醫院藥房、零售藥房、在線藥房等。由於醫院藥房中阿達木單抗的高可用性，預計醫院藥房將顯示出最高的市場增長。醫院越來越多地使用阿達木單抗治療自身免疫性疾病和皮膚病。阿達木單抗可有效減輕與某些疾病相關的疼痛和腫脹。

區域分析

北美佔阿達木單抗全球市場的最大份額。

由於類風濕性關節炎 (RA)、銀屑病關節炎、克羅恩病、斑塊狀銀屑病和潰瘍性結腸炎的高發病率，北美地區在 2021 年佔全球阿達木單抗市場的最大份額。根據美國銀屑病基金會的數據，美國約有 100 萬人患有銀屑病關節炎。根據美國國家關節炎、肌肉骨骼和皮膚病研究所的數據，斑塊型銀屑病是最常見的銀屑病形式，在美國影響了大約 670 萬成年人。根據美國國立衛生研究院的數據，美國克羅恩病的患病率為每 10 萬人 201 人。

由於對阿達木單抗的優惠報銷，美國擁有最高的市場份額。有多個市場參與者正在開發阿達木單抗。研究阿達木單抗在類風濕性關節炎 (RA)、銀屑病關節炎、克羅恩病和潰瘍性結腸炎以外的適應症方面的潛力的研發活動也在增加。預計在預測期內，先進的醫療保健設施和基礎設施將推動市場發展。

預計亞太地區將在預測期內以最快的複合年增長率增長

由於不健康的生活方式、日常生活壓力和免疫系統功能障礙導致自身免疫性疾病患病率增加，據估計，亞太地區是全球阿達木單抗市場增長最快的地區。 .預計不斷增長的老年人口也將對市場產生積極影響。聯合國報告稱，印度約有 8700 萬 65 歲及以上的人口。對醫療設施和基礎設施的投資也在增加。提高對自身免疫性疾病的認識，對市場產生積極影響。

由於對生物仿製藥的有利法規，阿達木單抗生物仿製藥正在獲得批准。例如，2020年9月，InnoVent Biologics獲得中國國家藥品監督管理局（NMPA）批准的類風濕關節炎（RA）重組人抗TNF-α單克隆抗體製劑Surinno（阿達木單抗注射液）獲批用於治療強直性脊柱炎和牛皮癬。由於國內收入和購買力的提高，預計在預測期內對阿達木單抗的需求將增加。

競爭格局。

阿達木單抗市場分散，公司眾多。 AbbVie Inc、Amgen Inc、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company, Ltd、F. Hoffmann-La Roche Ltd、Glenmark Pharmaceuticals、Novartis AG 和 Pfizer Inc 將成為擁有重要市場份額的主要參與者。公司正在採取多種增長戰略，例如產品發布、收購、合併、合作夥伴關係和許可，以增加其市場佔有率。例如：

合併與合作。

2020 年 9 月，Sensyne Health plc 與牛津大學建立合作夥伴關係，開展一項臨床試驗，以評估阿達木單抗治療 COVID-19 的效果。根據協議條款， Sensyne 將為抗 TNF 藥物阿達木單抗預防 COVID-19引起的呼吸衰竭的 AVID-CC 2期臨床試驗提供遠程數據收集和分析軟件。

產品發布和批准

2021 年 2 月 24 日，艾伯維獲得美國食品藥品監督管理局 (FDA) 對 HUMIRA（阿達木單抗）的批准。 HUMIRA 是一種皮下生物製劑，適用於 5 歲及以上患有中度至重度活動性潰瘍性結腸炎的兒科患者。

2021 年 5 月 5 日，加拿大安進公司推出了引用 Humira 的阿達木單抗生物類似藥 (Amjevita)。該生物仿製藥產品適用於參考產品的所有適應症。這種amjevita包括類風濕性關節炎、銀屑病關節炎、多關節幼年特發性關節炎、克羅恩病、強直性脊柱炎和潰瘍性結腸炎。現在在加拿大有售。

2019 年 11 月 18 日，輝瑞公司宣布已獲得美國食品和藥物管理局 (FDA) 的批准，將 ABRILADA (adalimumab-afzb) 作為 Humira (adalimumab) 的生物仿製藥。 Abrilah 用於治療患有類風濕性關節炎、銀屑病關節炎、強直性脊柱炎、幼年特發性關節炎、成人克羅恩病、潰瘍性結腸炎和尋常型銀屑病的特定患者。

明白了。

2020 年 5 月，AbbVie 收購了 Allergan plc。

與

合作。

2020 年 3 月，Albotech HF 與 DKSH 就艾伯維（AbbVie）的 Humira（阿達木單抗）生物仿製藥 AVT02在亞太地區（APAC）市場的商業化簽訂了獨家許可協議。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按疾病類型劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 自身免疫性疾病的患病率不斷上升
      • 優惠的保險報銷範圍
    • 限制因素
      • 與使用阿達木單抗相關的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型

  • 類風濕性關節炎 (RA)
  • 銀屑病關節炎 (PsA)
  • 克羅恩病 (CD)
  • 強直性脊柱炎 (AS)
  • 斑塊狀銀屑病 (Ps)
  • 潰瘍性結腸炎
  • 其他

第 8 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • 艾伯維公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals
  • Hetero Healthcare Limited
  • Novartis AG
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Mylan N.V
  • Emcure Pharmaceuticals Ltd.
  • Cipla Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd.
  • Terumo Corp.
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.（LIST NOT EXHAUSTIVE）

第12章 DataM

簡介目錄
Product Code: DMPH2788

Market Overview

Adalimumab market was valued at USD 3829.40 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Adalimumab is approved under the brand name Humira for the treatment of Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn's Disease (CD), and Plaque Psoriasis (Ps). Adalimumab is a recombinant human IgG 1 monoclonal antibody that targets tumour necrosis factor (TNF). It acts by binding to the tumour necrosis factor (TNF) and inhibiting its interaction with the p55 and p75 cell surface TNF receptors. It lyses surface tumour necrosis factor expressing cells. It is effective in modulating the biological responses induced or regulated by TNF involving the changes in the levels of adhesion molecules responsible for leukocyte migration.

Adalimumab is developed by using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system. It is supplied as either a single-use, prefilled pen or as a single-use, 1 mL filled glass syringe.

Market Dynamics

Rising Prevalence of Autoimmune Disorders is Driving the Growth of the Market

The market is driven by the increasing demand for adalimumab with the increasing prevalence of autoimmune diseases. According to the National Stem Cell Foundation (NSCF), approximately 4% of the world's population is suffering from one autoimmune disease. Rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, plaque psoriasis, and others are the most common autoimmune diseases. According to the National Psoriasis Foundation, approximately 2% to 3% of the global population i.e., 125 million people are suffering from Psoriasis worldwide. Approximately, 30% of patients with psoriasis develop psoriatic arthritis, chronic inflammatory arthritis that leads to joint deformations and disability. Ankylosing spondylitis affects around 0.1% and 1.4% of people worldwide. It is most frequent in men in comparison to women. According to the Arthitis Foundation, around 80% of people develops the symptoms of ankylosing spondylitis in the age group at or before age of 30 years. Around, 5% of patients would develop ankylosing spondylitis in the age group of 45 or older.

Favorable Reimbursement Coverage for Adalimumab is Boosting the Market Growth

The better availability of the reimbursement coverage for adalimumab shall stimulate market growth. Around, 99% of national commercial, Medicare Part D, and Medicaid patients cover the adalimumab. Chinese regulators had also included adalimumab in the country's National Reimbursement Drug List (NRDL). Chinese regulators provide with an average of 61% in price cuts of adalimumab with pharma companies.

Adverse Effects Associated with the use of Adalimumab is Hampering the Market Growth

The market is hindered by the adverse effects associated with the use of the adalimumab. Several adverse effects such as nausea, abdominal pain, hyperlipidemia, hematuria, hypercholesterolemia, back pain, rash, headache, hypertension, and others are observed among the patients. Redness, swelling or pain is observed at the site of injection of the adalimumab. It also increases the risk of developing a fungal, bacterial, and viral infection that can spread through the body. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been observed among the patients treated with adalimumab.

COVID-19 Impact Analysis

The global adalimumab market has received immense impetus from the COVID-19 pandemic, as several institutes, organizations, and companies are focussing on evaluating the potential of adalimumab for the treatment of the COVID-19. There is increasing research and development activities for adalimumab for the COVID-19. It has been observed that the COVID-19 patients who had administered the anti-TNF therapies for the treatment of inflammatory bowel disease and inflammatory arthritis were less likely to be hospitalised. The anti-TNF therapies are effective in neutralizing the TNF, a major component of the cytokine response part of the damaging excess inflammatory phase of COVID-19. Therefore, institutes and organizations are focussing on conducting clinical trials for examining the efficacy and safety of adalimumab among patients with COVID-19. For instance, in October 2020, Researchers at the University of Oxford in the United Kingdom had planned to initiate a new clinical trial to evaluate the effectiveness of the adalimumab for the treatment of the COVID-19 patients in community care settings, primarily in care homes. The clinical trial i.e., AVID-CC would be led by the Oxford Clinical Trials Research Unit (OCTRU) and would enroll up to 750 patients from community care homes.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Market Segment Analysis

The Rheumatoid Arthritis segment is expected to hold the largest share in the Adalimumab market

By disease type, the market is classified as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and others. The rheumatoid arthritis segment is anticipated to hold the largest share in the adalimumab treatment market. Rheumatoid arthritis is the most common autoimmune arthritis that affects the joints, connective tissues, muscle, tendons, and fibrous tissues. It is characterized by joint pain, stiffness, swelling and decreased movement of the joints. It causes pain and swelling in the wrist and small joints of the hand and feet. Rheumatoid Arthritis can hamper the patient's mobility and lead to permanent joint damage. The prevalence of rheumatoid arthritis is increasing worldwide. According to the World Health Organization (WHO), the prevalence of rheumatoid arthritis ranges between 0.3% and 1% across the globe. It is most frequent among women in comparison to men.

By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies are segmented to have the highest market growth due to the high availability of the adalimumab in the hospital pharmacies. There is a growing usage of the adalimumab for the treatment of autoimmune and skin disorders in hospitals. Adalimumab is effective in reducing the pain, and swelling associated with several disorders.

Geographical Analysis

North America region holds the largest market share global Adalimumab market

North America region is dominating the global adalimumab market accounted for the largest market share in 2021 owing to the high prevalence of Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, Plaque Psoriasis, and Ulcerative Colitis. According to the National Psoriasis Foundation, around one million people are being affected by Psoriatic Arthritis in the United States. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Plaque Psoriasis is the most frequent form of psoriasis that affects around 6.7 million adults in the United States. As per the National Institute of Health, the prevalence of Crohn's Disease was 201 per 100,000 in the United States.

The United States accounts for the highest market share due to the availability of favorable reimbursement coverage for adalimumab. There is a presence of several market players developing adalimumab. There is increasing research and development activities for examining the potential of adalimumab for the treatment of other indications apart from Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis. The availability of advanced healthcare facilities and infrastructure shall stimulate the market over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global adalimumab market owing to the increasing prevalence of autoimmune diseases with the increasing adoption of unhealthy lifestyles, stress in daily life & immune system malfunction. The growing elder population shall have a positive impact on the market. According to the United Nations Report, there were around 87 million of the population of age-group 65 years or over in India. There is increasing investment for the improvement of the healthcare facilities & infrastructure. There is increasing awareness that autoimmune diseases shall have a positive impact on the market.

There is an increase in the approval of the biosimilars of adalimumab due to the presence of favorable regulatory policies for biosimilars. For instance, in September 2020, Innovent Biologics, Inc. had received the approval for Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug from the National Medical Products Administration (NMPA) of China for the treatment of Rheumatoid Arthritis (RA), ankylosing spondylitis and psoriasis in China. The increasing domestic income and purchasing power of people shall boost the demand for adalimumab over the forecasted period.

Competitive Landscape:

The adalimumab market studied is a fragmented market with the presence of a large number of market players. AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals, Novartis AG, and Pfizer Inc are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In September 2020, Sensyne Health plc had entered into the collaboration with the University of Oxford for conducting the clinical trial for evaluating the adalimumab for the treatment of COVID-19. Under the terms of the agreement, Sensyne would provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19

Product Launch & Approvals:

On 24th February 2021, AbbVie. had received approval for HUMIRA (adalimumab) from the United States Food and Drug Administration (FDA). The HUMIRA is the subcutaneous biologic treatment for pediatric patients 5 years of age and older with moderately to severely active ulcerative colitis.

On 5th May 2021, Amgen Canada launched Its adalimumab biosimilar (Amgevita), referencing Humira. The biosimilar product is available for all indications of the reference product. This Amgevita includes rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease, ankylosing spondylitis, and ulcerative colitis. It is now available in Canada.

On 18th November 2019, Pfizer Inc. announced that it received approval from the United States Food and Drug Administration (FDA) for ABRILADA (adalimumab-afzb) as a biosimilar to Humira (adalimumab). The ABRILADA is used to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

Acquisition:

In May 2020, AbbVie had acquired the Allergan plc

Partnership:

In March 2020, Alvotech HF had entered into an exclusive license partnership with DKSH for the commercialization of AVT02, a biosimilar to AbbVie's HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Autoimmune Disorders
      • 4.1.1.2. Favorable Reimbursement Coverage
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Adverse Effects Associated with the Use of Adalimumab
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Rheumatoid Arthritis (RA)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Psoriatic Arthritis (PsA)
    • 7.3.3. Crohn's Disease (CD)
    • 7.3.4. Ankylosing Spondylitis (AS)
    • 7.3.5. Plaque Psoriasis (Ps)
    • 7.3.6. Ulcerative Colitis
    • 7.3.7. Others

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospitals Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. The Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. AbbVie Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Amgen Inc.
  • 11.3. Boehringer Ingelheim International GmbH
  • 11.4. Bristol-Myers Squibb Company
  • 11.5. Cadila Healthcare Ltd.
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Glenmark Pharmaceuticals
  • 11.8. Hetero Healthcare Limited
  • 11.9. Novartis AG
  • 11.10. Pfizer Inc.
  • 11.11. Torrent Pharmaceuticals Ltd.
  • 11.12. Mylan N.V
  • 11.13. Emcure Pharmaceuticals Ltd.
  • 11.14. Cipla Inc.
  • 11.15. Reliance Life Sciences
  • 11.16. Samsung Bioepis Co Ltd.
  • 11.17. Terumo Corp.
  • 11.18. Fujifilm Kyowa Kirin Biologics Co. Ltd.(LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us